source
- Iambic Therapeutics eyes IPO as it pushes HER2 inhibitor IAM1363 into early trialsIambic Therapeutics, a San Diego AI‑driven biotech, said it is preparing for an initial public offering after securing several large‑scale partnerships with major pharmaceutical companies. In its…
- Trump Medicaid pricing plan may give Novo Nordisk unexpected financial boostSTAT reports that the White House introduced a plan aimed at lowering the cost of drugs for Medicaid beneficiaries. The policy includes provisions that reduce prices of obesity treatments for senio…